Patents by Inventor Christopher Robert Bebbington

Christopher Robert Bebbington has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11203638
    Abstract: The present disclosure provides methods for the treatment of an allergic ocular disease (e.g., allergic conjunctivitis, keratoconjunctivitis, or giant papillary conjunctivitis). In particular, the present disclosure provides methods for the treatment of an allergic ocular disease through administration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of an allergic ocular disease.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: December 21, 2021
    Assignee: ALLAKOS INC.
    Inventors: Christopher Robert Bebbington, Bradford Andrew Youngblood, Nenad Tomasevic
  • Publication number: 20210246205
    Abstract: The present disclosure provides methods for the treatment of chronic urticaria. In particular, the present disclosure provides methods for the treatment of chronic urticaria through administration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of chronic urticaria.
    Type: Application
    Filed: May 3, 2019
    Publication date: August 12, 2021
    Inventors: Christopher Robert BEBBINGTON, Nenad TOMASEVIC, Henrik RASMUSSEN
  • Publication number: 20210107977
    Abstract: The invention provides methods and compositions for the prevention or treatment of fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis. In particular, the invention provides methods for the prevention or treatment of fibrotic diseases and pre-fibrotic diseases through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention or treatment fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis.
    Type: Application
    Filed: July 31, 2020
    Publication date: April 15, 2021
    Inventors: Christopher Robert BEBBINGTON, Nenad TOMASEVIC, Rustom FALAHATI, Bradford Andrew YOUNGBLOOD
  • Patent number: 10919983
    Abstract: The invention provides methods for generating human antibodies with the specificity of a reference antibody by replacement of portions of the VH and VL sequences of the reference antibody with sequences from human antibody repertoires. The invention also provides novel compositions comprising hybrid immunoglobulin variable domains containing a combination of frameworks (FRs) and CDRs from different antibody clones.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: February 16, 2021
    Assignee: HUMANIGEN, INC.
    Inventors: Christopher Robert Bebbington, Kenneth R. Luehrsen, Geoffrey T. Yarranton
  • Patent number: 10774145
    Abstract: The invention provides methods and compositions for the prevention or treatment of fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis. In particular, the invention provides methods for the prevention or treatment of fibrotic diseases and pre-fibrotic diseases through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention or treatment fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: September 15, 2020
    Assignee: Allakos Inc.
    Inventors: Christopher Robert Bebbington, Nenad Tomasevic, Rustom Falahati, Bradford Andrew Youngblood
  • Publication number: 20200270344
    Abstract: The present disclosure provides methods for the treatment of inflammatory bowel disease (IBD) or an eosinophilic gastrointestinal disorder (EGID), such as eosinophilic esophagitis (EOE), eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), and eosinophilic colitis (EC). In particular, the present disclosure provides methods for the treatment of IBD or an EGID through administration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of IBD or an EGID.
    Type: Application
    Filed: May 4, 2018
    Publication date: August 27, 2020
    Inventors: Christopher Robert BEBBINGTON, Bradford Andrew YOUNGBLOOD, Nenad TOMASEVIC, Emily C. BROCK
  • Publication number: 20200181270
    Abstract: The invention provides methods and compositions for the prevention and treatment of advanced systemic mastocytosis such as systemic mastocytosis with an associated hematologic non-mast-cell lineage disease (SM-AHNMD). In particular, the invention provides methods for the prevention and treatment of advanced systemic mastocytosis through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention and treatment of advanced systemic mastocytosis such as SM-AHNMD.
    Type: Application
    Filed: February 20, 2020
    Publication date: June 11, 2020
    Inventors: Christopher Robert BEBBINGTON, Nenad TOMASEVIC, Rustom FALAHATI
  • Publication number: 20200148766
    Abstract: The present disclosure provides methods for the treatment of an allergic ocular disease (e.g., allergic conjunctivitis, keratoconjunctivitis, or giant papillary conjunctivitis). In particular, the present disclosure provides methods for the treatment of an allergic ocular disease through administration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of an allergic ocular disease.
    Type: Application
    Filed: May 4, 2018
    Publication date: May 14, 2020
    Inventors: Christopher Robert BEBBINGTON, Bradford Andrew YOUNGBLOOD, Nenad TOMASEVIC
  • Patent number: 10604577
    Abstract: The invention provides methods and compositions for the prevention and treatment of advanced systemic mastocytosis such as systemic mastocytosis with an associated hematologic non-mast-cell lineage disease (SM-AHNMD). In particular, the invention provides methods for the prevention and treatment of advanced systemic mastocytosis through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention and treatment of advanced systemic mastocytosis such as SM-AHNMD.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: March 31, 2020
    Assignee: Allakos Inc.
    Inventors: Christopher Robert Bebbington, Nenad Tomasevic, Rustom Falahati
  • Publication number: 20190338027
    Abstract: The present disclosure provides methods for the treatment of chronic obstructive pulmonary disease (COPD) (e.g., non-eosinophilic COPD). In particular, the present disclosure provides methods for the treatment of COPD (e.g., non-eosinophilic COPD) through administration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of COPD (e.g., non-eosinophilic COPD).
    Type: Application
    Filed: January 5, 2018
    Publication date: November 7, 2019
    Applicant: Allakos Inc.
    Inventors: Bradford Andrew YOUNGBLOOD, Nenad TOMASEVIC, Christopher Robert BEBBINGTON
  • Patent number: 10183996
    Abstract: The invention provides methods and compositions for the prevention and treatment of Siglec-8 associated diseases such as chronic rhino sinusitis with concomitant asthma and aspirin-exacerbated respiratory disease. In particular, the invention provides methods for the prevention and treatment of Siglec-8 associated diseases through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention and treatment of Siglec-8 associated diseases such as chronic rhinosinusitis with concomitant asthma and aspirin-exacerbated respiratory disease.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: January 22, 2019
    Assignee: Allakos Inc.
    Inventors: Christopher Robert Bebbington, Nenad Tomasevic, Rustom Falahati
  • Publication number: 20180179279
    Abstract: The invention provides methods and compositions for the prevention or treatment of fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis. In particular, the invention provides methods for the prevention or treatment of fibrotic diseases and pre-fibrotic diseases through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention or treatment fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis.
    Type: Application
    Filed: June 16, 2016
    Publication date: June 28, 2018
    Inventors: Christopher Robert BEBBINGTON, Nenad TOMASEVIC, Rustom FALAHATI, Bradford Andrew YOUNGBLOOD
  • Publication number: 20170114138
    Abstract: The invention provides methods and compositions for the prevention and treatment of advanced systemic mastocytosis such as systemic mastocytosis with an associated hematologic non-mast-cell lineage disease (SM-AHNMD). In particular, the invention provides methods for the prevention and treatment of advanced systemic mastocytosis through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention and treatment of advanced systemic mastocytosis such as SM-AHNMD.
    Type: Application
    Filed: October 20, 2016
    Publication date: April 27, 2017
    Inventors: Christopher Robert BEBBINGTON, Nenad TOMASEVIC, Rustom FALAHATI
  • Publication number: 20170073413
    Abstract: The invention provides methods and compositions for the prevention and treatment of Siglec-8 associated diseases such as chronic rhino sinusitis with concomitant asthma and aspirin-exacerbated respiratory disease. In particular, the invention provides methods for the prevention and treatment of Siglec-8 associated diseases through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention and treatment of Siglec-8 associated diseases such as chronic rhinosinusitis with concomitant asthma and aspirin-exacerbated respiratory disease.
    Type: Application
    Filed: February 27, 2015
    Publication date: March 16, 2017
    Inventors: Christopher Robert BEBBINGTON, Nenad TOMASEVIC, Rustom FALAHATI
  • Publication number: 20160102152
    Abstract: The invention provides methods for generating human antibodies with the specificity of a reference antibody by replacement of portions of the VH and VL sequences of the reference antibody with sequences from human antibody repertoires. The invention also provides novel compositions comprising hybrid immunoglobulin variable domains containing a combination of frameworks (FRs) and CDRs from different antibody clones.
    Type: Application
    Filed: December 14, 2015
    Publication date: April 14, 2016
    Inventors: Christopher Robert Bebbington, Kenneth R. Luehrsen, Geoffrey T. Yarranton
  • Patent number: 8354251
    Abstract: The present invention is directed generally to compositions and methods for expressing recombinant proteins in a mammalian host cell using a co-expressed transcriptional activator. In particular, the invention provides vectors, host cells, and methods of expressing at least one desired polypeptide by transfecting a mammalian host cell with cistrons encoding a transactivator, a desired polypeptide, and an apoptosis-protective protein.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: January 15, 2013
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher Robert Bebbington, Bo Yu
  • Patent number: 8084249
    Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: December 27, 2011
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers
  • Publication number: 20110065173
    Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.
    Type: Application
    Filed: February 26, 2010
    Publication date: March 17, 2011
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers
  • Publication number: 20110052577
    Abstract: The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.
    Type: Application
    Filed: July 28, 2010
    Publication date: March 3, 2011
    Applicant: Oxford Biomedica (UK) Limited
    Inventors: Alan Kingsman, Susan Mary Kingsman, Christopher Robert Bebbington, Miles William Carroll, Fiona Margaret Ellard, Kevin Alan Myers
  • Publication number: 20100040539
    Abstract: The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.
    Type: Application
    Filed: May 15, 2008
    Publication date: February 18, 2010
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Alan Kingsman, Susan Mary Kingsman, Christopher Robert Bebbington, Miles William Carroll, Fiona Margaret Ellard, Kevin Alan Myers